While on the one hand, the excessive release of inflammatory mediators, such as interleukin-1β (IL-1β) and IL-18, trigger abnormal systemic inflammatory reactions, accelerating tumor progression and increasing tumor burden, on the other hand, it promotes immunogenic cell death, enhances immune activity, and selectively kills tumor cells, exhibiting potential anti-tumor activity [31,32]. Here, IL18 is linked to neoplasm.